Pituitary-adrenocortical hyperfunction and intolerance to fluvoxamine, a selective serotonin uptake inhibitor.
Of nine nonsuppressors on the dexamethasone suppression test (DST), five (56%) developed intolerable side effects during treatment with fluvoxamine, a new serotonin uptake inhibiting antidepressant, compared with three of 24 suppressors (13%).
Brown
W A
WA
Arato
M
M
Shrivastava
R
R
D000328:Adult; D000928:Antidepressive Agents / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D003907:Dexamethasone; D004311:Double-Blind Method; D005260:Female; D016666:Fluvoxamine; D006801:Humans; D006854:Hydrocortisone / Q000097:blood*; D008297:Male; D009325:Nausea / Q000139:chemically induced; D010091:Oximes / Q000009:adverse effects*; D012702:Serotonin Antagonists / Q000009:adverse effects; D014839:Vomiting / Q000139:chemically induced
D000928:Antidepressive Agents; D010091:Oximes; D012702:Serotonin Antagonists; D003907:Dexamethasone; D016666:Fluvoxamine; D006854:Hydrocortisone